接种COVID-19疫苗与炎症性肠病发作相关吗?基于英国CPRD的自控病例系列分析
基于英国临床实践研究数据链,采用自控病例系列分析纳入1911例接种COVID-19疫苗的炎症性肠病患者,评估接种后21天内疾病发作风险。结果显示接种暴露期炎症性肠病总体、溃疡性结肠炎和克罗恩病的发作风险均未升高,按剂次、既往感染史和疫苗类型分层结果一致。
要点
- 接种COVID-19疫苗后21天内炎症性肠病发作风险未升高(总体aIRR 0.89,95%CI 0.77-1.02)。
- 溃疡性结肠炎患者接种后发作风险未升高(aIRR 0.79,95%CI 0.66-0.95)。
- 按剂次、既往COVID-19感染史和疫苗类型分层均未发现发作风险升高。
核心结论
- 接种COVID-19疫苗与炎症性肠病发作无关,无论既往是否感染COVID-19或使用信使RNA疫苗还是DNA疫苗。
研究设计与样本
- 采用自控病例系列分析,数据来自英国临床实践研究数据链,纳入2020年12月1日至2021年12月31日期间因疾病发作就诊的接种COVID-19疫苗的炎症性肠病患者1911例,52%为女性,平均年龄49岁,约63%为溃疡性结肠炎。
主要发现
- 所有疫苗接种合计的暴露期内,炎症性肠病总体aIRR为0.89(95%CI 0.77-1.02),溃疡性结肠炎为0.79(95%CI 0.66-0.95),克罗恩病为1.00(95%CI 0.79-1.27)。
- 仅纳入第一剂、第二剂或第三剂COVID-19疫苗时,暴露期内接种与炎症性肠病发作均无显著关联,aIRR分别为0.87(95%CI 0.71-1.06)、0.93(95%CI 0.75-1.15)和0.86(95%CI 0.63-1.17)。
- 按疫苗接种前是否有COVID-19感染史以及按接种载体DNA疫苗或信使RNA疫苗分层,均未发现任何亚组中发作风险升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare between December 1, 2020, and December 31, 2021, were ascertained from the Clinical Practice Research Datalink. IBD flares were identified using consultation and corticosteroid prescription records. Vaccinations were identified using product codes and vaccination dates. The study period was partitioned into vaccine-exposed (vaccination date and 21 days immediately after), prevaccination (7 days immediately before vaccination), and the remaining vaccine-unexposed periods. Participants contributed data with multiple vaccinations and IBD flares. Season-adjusted incidence rate ratios (aIRR) and 95% confidence intervals (CI) were calculated using self-controlled case series analysis. RESULTS: Data for 1911 cases with IBD were included; 52% of them were female, and their mean age was 49 years. Approximately 63% of participants had ulcerative colitis (UC). COVID-19 vaccination was not associated with increased IBD flares in the vaccine-exposed period when all vaccinations were considered (aIRR [95% CI] 0.89 [0.77-1.02], 0.79 [0.66-0.95], and 1.00 [0.79-1.27] in IBD overall, UC, and Crohn's disease, respectively). Analyses stratified to include only first, second, or third COVID-19 vaccinations found no significant association between vaccination and IBD flares in the vaccine-exposed period (aIRR [95% CI] 0.87 [0.71-1.06], 0.93 [0.75-1.15], and 0.86 [0.63-1.17], respectively). Similarly, stratification by COVID-19 before vaccination and by vaccination with vectored DNA or messenger RNA vaccine did not reveal an increased risk of flare in any of these subgroups. DISCUSSION: Vaccination against COVID-19 was not associated with IBD flares regardless of prior COVID-19 infection and whether messenger RNA or DNA vaccines were used.
引用
- Card TR, Nakafero G, Grainge MJ, et al. Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. Am J Gastroenterol. 2023. PMID: 36826512. doi:10.14309/ajg.0000000000002205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。